Zobrazeno 1 - 10
of 173
pro vyhledávání: '"59"'
Autor:
Ian Chau, Kabir Mohammed, Bhupinder Sharma, Alinane Munyenyembe, Tasneem Elnafie, Tatiana Elwes, Dima El-Sharkawi, David Cunningham, Sunil Iyengar, Sarah Thompson, Wilam Alfred
Publikováno v:
Blood. 136:31-32
Introduction Following completion of chemotherapy with curative intent for DLBCL, for those in remission (CR), numerous national and international guidelines suggest on-going follow-up primarily to detect relapse of disease. For example, the NCCN gui
Publikováno v:
Blood. 128:5179-5179
Background: Acute promyelocytic leukemia (APL) has a favorable prognosis with high complete remission rates of over 90 percent, with relapse occurring in only 10 to 15 percent of patients. Our objective was to describe the characteristics of relapsed
Autor:
Hartmut Döhner, Nigel J. Waters, Andrei V Krivstov, Martin S. Tallman, Greg Fine, Jesus G. Berdeja, Richard Koche, Scott A. Armstrong, Guillermo Garcia-Manero, Raoul Tibes, Blythe Thomson, David A. Rizzieri, Stephen J. Blakemore, Bob Löwenberg, Eytan M. Stein, Mojca Jongen-Lavrencic, Jessica K. Altman, Scott R. Daigle, Peter T.C. Ho
Publikováno v:
Blood. 126:2547-2547
Introduction: Aberrant fusion proteins involving the MLL histone methyltransferase (HMT) result in recruitment of another HMT, DOT1L, to a multi-protein complex. This leads to abnormal methylation of Histone H3 lysine 79 (H3K79) at MLL target genes a
Publikováno v:
Blood. 126:955-955
Introduction: Following the seminal study by Guyatt et al., serum ferritin has been widely accepted as the most accurate surrogate marker for iron deficiency, particularly if ferritin levels are < 45 mg/L. However, as an acute-phase reactant, ferriti
Autor:
Ellen D. McPhail, Amie E. Jackson, Anastasios Stathis, Michael Mian, Franco Cavalli, Christina Kalpadakis, Thomas M. Habermann, Emanuele Zucca, Elena Porro, Grzegorz S. Nowakowski, Gerassimos A. Pangalis, Kay M. Ristow
Publikováno v:
Blood. 124:1637-1637
Background: The salivary gland is one of the most common sites of involvement by non-gastric extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT). This multicenter, international trial sought to characterize the clinical cou
Publikováno v:
Blood. 124:1310-1310
Introduction CML management has rapidly changed in the last decade. Data are critically needed to characterize disease treatment, management, and drug use (particularly TKIs, tyrosine kinase inhibitors) to ultimately inform how to improve outcomes in
Autor:
Ann-Kathrin Eisfeld, Richard A. Larson, Wendy Stock, Donna Bucci, Andrew J Caroll, Richard Stone, Timothy S. Pardee, Jonathan E. Kolitz, Weiqiang Zhao, Guido Marcucci, Meir Wetzler, Clara D. Bloomfield, Geoffrey L. Uy, William Blum, Susan Geyer
Publikováno v:
Blood. 124:8-8
In AML, t(8;21)(q22;q22) and inv(16)(p13q22)/t(16;16)(p13;q22) and corresponding molecular rearrangements RUNX1/RUNX1T1 and CBFB/MYH11 (each involving a gene encoding a subunit of CBF) predict for favorable outcome in patients (pts) receiving consoli
Autor:
David C. Linch, Nick Chadwick, Anton Kruger, Deborah Turner, John Radford, Eliza A Hawkes, Kirit M. Ardeshna, Paul Smith, David Cunningham, Peter Johnson, Wendi Qian, Mary Gleeson, Paul R Mouncey, John Davies, Christopher Pocock, Andrew McMillan, Joanna Gambell, Andrew Jack
Publikováno v:
Blood. 124:1723-1723
Background: Central Nervous System (CNS) relapse of Diffuse Large B-cell Lymphoma (DLBCL) is associated with a poor prognosis. Prior to the advent of rituximab the incidence of CNS relapse without CNS prophylaxis was around 5% in most unselected seri
Publikováno v:
Blood. 122:5579-5579
Background Vaso-occlusive crisis (VOC) management of patients with sickle cell disease (SCD) in emergency departments (EDs) is typically reported as sub-optimal. As part of a larger research and quality improvement study, a nurse-initiated high dose,
Publikováno v:
Blood. 122:4678-4678
Glomerulopathy, associated with initial glomerular hyperfiltration followed by the development of microalbuminuria/proteinuria, is a well recognised complication of Sickle Cell Disease. There is evidence for the efficacy of Angiotensin-Converting Enz